BELKYRA® Double Chin Treatment

BELKYRA
Belkyra 2021 1st

Double chin is characterized by localized fat accumulation in the submental region, making people feel older and more overweight than they actually are, and brings impact to both men and women.

Double chin maybe due to:

  • Genetics

  • Aging

  • Weight Change

The only FDA approved treatment for undesirable submental fullness 

Belkyra is a new, patented formulation of Deoxycholic Acid (DCA), which is biologically equivalent to naturally occurring molecule. 

 

Targeting submental fullness, Belkyra disrupts adipocyte membranes, leading to irreversible fat cell breakdown. 

  • Permanently destroy fat cells

  • Non-surgical procedure 

  • US FDA and EMA approved 

  • The only FDA approved treatment for undesirable submental fullness 

  • Average 2-4 treatment sessions for permanent fat cell breakdown

  • Research proven - Long-term safety study data up to 5 years 

Related Treatments:

*療程效果視乎個人體質,因人而異